Natalie Harp's Cancer Story Questioned After Claiming Trump Law Saved Her Despite Taking Treatment Before It

For years, Natalie Harp has presented herself as the cancer survivor whose life was saved by Donald Trump and his signature on the Right to Try Act. But a growing review of her public statements, treatment timeline and medical claims is now putting that dramatic story under an uncomfortable spotlight.

A podcast discussing the allegations pointed to one particularly striking detail: Harp reportedly wrote about taking the treatment she later linked to Trump's law before the law had even been signed.

The allegation remains disputed, but the timeline has prompted renewed scrutiny of a story that helped propel Harp from political outsider to a member of Trump's White House orbit.

Harp's Trump Rescue Story Goes Back Years

Harp's public account became prominent in 2019, when she described surviving a serious medical error before being diagnosed with rare and terminal bone cancer. She said conventional treatments had failed and that clinical trials had rejected her.

Her story then placed Trump at the centre of her survival. She credited his support for the Right to Try Act, signed on 30 May 2018, with opening the door to treatment that ultimately helped keep her alive.

In one widely circulated account, Harp described herself as someone who had been given little hope and portrayed Trump's legislation as the breakthrough that changed everything.

She later repeated the story at Republican events, including the 2020 Republican National Convention, where she told Trump that she would not be alive without him.

The podcast host noted the political importance of that narrative, saying, 'The story she told doesn't match the law she credited or the disease she named.'

Her Treatment Timeline Is Now Under Scrutiny

According to the material cited in the podcast, Harp posted on social media on 27 March 2018 about the chemotherapy or treatment she was receiving. That was more than two months before Trump signed the Right to Try Act.

That distinction matters because the law was designed to give certain eligible patients access to investigational drugs that had not yet received full FDA approval. By contrast, doctors can already prescribe approved medicines for uses that have not been specifically approved by the FDA, a practice known as off-label prescribing.

The podcast therefore questioned how a treatment Harp was already receiving in March could later be presented as something made possible by legislation signed in May.

The host described it as the central contradiction, saying, 'She was already taking it an off-label prescription, perfectly legal two months before the law.'

Questions Also Surround Her Cancer Account

Harp has described having stage two bone cancer and said that available chemotherapy options had failed her. The podcast argues that some elements of this account appear difficult to reconcile with established descriptions of how bone cancers such as osteosarcoma are generally treated.

The discussion also highlighted Harp's claims that clinical trials repeatedly rejected her. The podcast questioned why a patient with a rare cancer would supposedly have struggled to find trials, given the need for suitable participants in rare disease research.

None of those discrepancies proves that Harp was never seriously ill. Cancer can present differently between patients, and individual treatment decisions depend on circumstances that may not be visible in public records.